Showing 3921-3930 of 4045 results for "".
- FDA Approves Combination Use of GSK's Mekinist® (trametinib) and Tafinlar® (dabrafenib)https://practicaldermatology.com/news/20140109-fda_approves_combination_use_of_gsks_mekinist_trametinib_and_tafinlar_dabrafenib/2459375/GlaxoSmithKline plc [LSE/NYSE: GSK] has received FDA approval of Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutation
- Theradome Laser Helmet Launches for At-home Treatment of Hair Losshttps://practicaldermatology.com/news/20131219-theradome_laser_helmet_launches_for_at-home_treatment_of_hair_loss/2459389/Theradome Laser Helmet LH80 PRO, the first FDA and over-the-counter cleared, wearable laser hair restoration treatment, is now available. Developed for in-home use and designed for patients suffering from the effects of thinning hair and Androge
- FDA Approves Varithena to Treat Varicose Veinshttps://practicaldermatology.com/news/20131127-fda_approved_varithena_to_treat_varicose_veins/2459401/The FDA recently approved BTG plc's Varithena (polidocanol injectable foam) for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. V
- Investigational Melanoma Agent Improves Survival in Phase III Trialhttps://practicaldermatology.com/news/20131120-investigational_melanoma_agent_improves_survival_in_phase_iii_trial/2459408/Interim results from a pivotal Phase III trial show that Amgen's investigational agent talimogene laherpaepvec increased overall survival in patients with unresected stage IIIB, IIIC, or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). The study found that median ov
- Valeant's Antifungal Agent Luzu Wins FDA Approvalhttps://practicaldermatology.com/news/20131115-valeants_antifungal_luzu_wins_fda_approval/2459414/The FDA has approved Luzu® (luliconazole, Valeant) Cream, 1% for the topical treatment of athlete's foot (interdigital tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis), caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and olde
- Clinical Significance and Benefit from Scenesse in US Phase III EPP Studyhttps://practicaldermatology.com/news/20131113-clinical_significance_and_benefit_from_scenesse_in_us_phase_iii_epp_study/2459417/A Phase III study (CUV039) evaluating the administration of Scenesse (afamelanotide 16mg) to patients diagnosed with erythropoietic protoporphyria (EPP) has shown a clinically meaningful treatment effect, according to Clinuvel P
- MELA Sciences Appoints Rose Crane as President and Chief Executive Officer and a Directorhttps://practicaldermatology.com/news/20131106-mela_sciences_appoints_rose_crane_as_president_and_chief_executive_officer_and_a_director/2459422/MELA Sciences, Inc. (MELA), the medical device company that has developed and is commercializing MelaFind(R), an optical diagnostic device using proprietary technology that enables dermatologists to “see” below the surface of a patient's skin to aid in the diagnosis of melanoma, today announced that
- Humira Found Effective for Hidradentis Suppurativahttps://practicaldermatology.com/news/20131011-humira_found_effective_for_hidradentis_suppurativa/2459436/Results from a post-hoc analysis of an investigational Phase II study found that Humira (adalimumab, AbbVie) induced significant response rate in adult patients with moderate to severe hidradenitis suppurativa (HS) after 16 weeks of therapy. Researchers used the HS-Physician Global Assessment (HS-P
- Cimzia FDA Approved to Treat Active Psoriatic Arthritis in Adultshttps://practicaldermatology.com/news/20131001-cimzia_receives_fda_approval_to_treat_adults_with_active_psoriatic_arthritis/2459446/The FDA recently approved UCB's Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA). The FDA approval of Cimzia for active PsA is based on data from the RAPID-PsA study, an ongoing, Phase III, multicenter, randomized,
- Nucletron Introduces Esteya Electronic Brachytherapy for Treating Skin Cancerhttps://practicaldermatology.com/news/20130923-nucletron_introduces_esteya_electronic_brachytherapy_for_treating_skin_cancer/2459456/Nucletron, an Elekta company, recently launched Esteya, a new approach for treating patients with skin cancer. Esteya electronic brachytherapy mimics proven high dose rate (HDR) brachytherapy by bringing a small X-ray source very close to the cancerous site, enabling the local a